{"id":4281,"date":"2025-09-04T09:56:07","date_gmt":"2025-09-04T06:56:07","guid":{"rendered":"https:\/\/pharmaworlddergi.com\/?p=4281"},"modified":"2025-09-04T16:15:58","modified_gmt":"2025-09-04T13:15:58","slug":"orzaksin-uretim-gucu-nuvita-ilac-ar-ge-yatirimiyla-turkiyenin-ilk-250-firmasi-arasinda","status":"publish","type":"post","link":"https:\/\/pharmaworlddergi.com\/?p=4281","title":{"rendered":"Orzaks\u2019\u0131n \u00dcretim G\u00fcc\u00fc Nuvita \u0130la\u00e7, Ar-Ge Yat\u0131r\u0131m\u0131yla T\u00fcrkiye\u2019nin \u0130lk 250 Firmas\u0131 Aras\u0131nda"},"content":{"rendered":"\n

Orzaks\u2019\u0131n \u00fcretim faaliyetlerini \u00fcstlenen stratejik \u00fcretim merkezi Nuvita \u0130la\u00e7, T\u00fcrkiye\u2019nin en fazla Ar-Ge yat\u0131r\u0131m\u0131 yapan 250 firmas\u0131 aras\u0131na girdi.<\/strong><\/p>\n\n\n\n

Ekonomi ve i\u015f d\u00fcnyas\u0131 portal\u0131 Turkishtime\u2019\u0131n gelenekselle\u015fen T\u00fcrkiye Ar-Ge 250 Ara\u015ft\u0131rmas\u0131\u2019n\u0131n 2024 verileriyle haz\u0131rlanan sonu\u00e7lar\u0131 a\u00e7\u0131kland\u0131. T\u00fcrkiye ihracat s\u0131ralamas\u0131ndaki ilk 500 firmaya, Bilim, Sanayi ve Teknoloji Bakanl\u0131\u011f\u0131\u2019na kay\u0131tl\u0131 Ar-Ge merkezi bulunan firmalara ve Ar-Ge datalar\u0131n\u0131 Kamu Ayd\u0131nlatma Platformu\u2019yla payla\u015fan firmalara y\u00f6nelik anket verileriyle haz\u0131rlanan ara\u015ft\u0131rma sonu\u00e7lar\u0131na g\u00f6re Orzaks\u2019\u0131n \u00fcretim g\u00fcc\u00fc olan Nuvita \u0130la\u00e7, performans\u0131yla ilk 250 firma aras\u0131nda yer ald\u0131.<\/p>\n\n\n\n

Kalite anlay\u0131\u015f\u0131 ve uluslararas\u0131 standartlara uygun \u00fcretim felsefesiyle bilime dayal\u0131 Ar-Ge faaliyetleri y\u00fcr\u00fcten Nuvita \u0130la\u00e7, ge\u00e7en seneki ara\u015ft\u0131rmada ilk 500 \u015firket aras\u0131ndayken, bu y\u0131lki Ar-Ge yat\u0131r\u0131mlar\u0131nda performans\u0131n\u0131 art\u0131rarak ilk 250 listesinde yer ald\u0131.<\/p>\n\n\n\n

Orzaks\u2019\u0131n \u00fcretim \u015firketi Nuvita \u0130la\u00e7\u2019\u0131n Ar-Ge Harcamalar\u0131 2021\u2019den bu yana 10 kat artt\u0131<\/strong><\/p>\n\n\n\n

Orzaks\u2019\u0131n \u00fcretim \u015firketi Nuvita \u0130la\u00e7, Ar-Ge harcamalar\u0131n\u0131 son 4 y\u0131lda 10 kat art\u0131rd\u0131. Toplamda 100 milyon TL\u2019yi a\u015fan yat\u0131r\u0131mlar\u0131yla, bilime ve inovasyona verdi\u011fi somut deste\u011fi ortaya koyan Nuvita \u0130la\u00e7\u2019\u0131n Ar-Ge Merkezi\u2019nde halen 38 proje y\u00fcr\u00fct\u00fcl\u00fcyor. Bug\u00fcne kadar 9 kamu projesinin tamamland\u0131\u011f\u0131 merkezde 2 kamu projesine y\u00f6nelik geli\u015ftirme \u00e7al\u0131\u015fmalar\u0131 ise devam ediyor. Nuvita \u0130la\u00e7\u2019\u0131n 2023\u2019te 2, 2024\u2019te 9 olmak \u00fczere 11 patent ba\u015fvurusu bulunuyor. <\/p>\n\n\n\n

\u201cSa\u011fl\u0131\u011fa de\u011fer katacak yenilik\u00e7i \u00e7\u00f6z\u00fcmler geli\u015ftiriyoruz\u201d<\/strong><\/p>\n\n\n

\n
\"\"<\/figure><\/div>\n\n\n

Nuvita \u0130la\u00e7 Ar-Ge M\u00fcd\u00fcr\u00fc Akif Kavak, Turkishtime T\u00fcrkiye Ar-Ge 250 Ara\u015ft\u0131rmas\u0131\u2019n\u0131n sonu\u00e7lar\u0131n\u0131 de\u011ferlendirdi. Nuvita \u0130la\u00e7\u2019\u0131n, \u015firket dinamikli\u011fini sa\u011flamak, de\u011fi\u015fen pazar taleplerini kar\u015f\u0131lamak ve stratejik \u00f6nemdeki hammaddelerin \u00fcretimi i\u00e7in Ar-Ge\u2019ye \u00f6nemli yat\u0131r\u0131mlar yapt\u0131\u011f\u0131n\u0131 belirten Kavak, \u015f\u00f6yle devam etti:<\/p>\n\n\n\n

\u201cAr-Ge ve inovasyona yapt\u0131\u011f\u0131m\u0131z yat\u0131r\u0131mlarla, \u015firketimizin b\u00fcy\u00fcmesinin yan\u0131nda \u00fclkemizin kalk\u0131nma hedeflerini de destekliyoruz. T\u00fcm bu faaliyetlerimizle bilimsel bilginin ekonomik de\u011fere d\u00f6n\u00fc\u015ft\u00fcr\u00fclmesini sa\u011flayarak hem akademiye hem de \u00f6zel sekt\u00f6re katk\u0131 sunuyoruz. <\/p>\n\n\n

\n
\"\"<\/figure><\/div>\n\n\n

Orzaks\u2019\u0131n da \u00fcretim faaliyetlerini s\u00fcrd\u00fcrd\u00fc\u011f\u00fc Ar-Ge merkezimizde devam eden inovatif projelerimiz ve patent ba\u015fvurular\u0131m\u0131zla literat\u00fcre ve sekt\u00f6re kal\u0131c\u0131 de\u011ferler kazand\u0131r\u0131yoruz. \u00d6zellikle stratejik hammaddelerin \u00fcretimi konusundaki \u00e7al\u0131\u015fmalar\u0131m\u0131zla \u00fclkemizin ihtiyac\u0131na cevap verirken, insan sa\u011fl\u0131\u011f\u0131na de\u011fer katacak yenilik\u00e7i \u00e7\u00f6z\u00fcmler geli\u015ftirmeye devam edece\u011fiz.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"

Orzaks\u2019\u0131n \u00fcretim faaliyetlerini \u00fcstlenen stratejik \u00fcretim merkezi Nuvita \u0130la\u00e7, T\u00fcrkiye\u2019nin en fazla Ar-Ge yat\u0131r\u0131m\u0131 yapan 250 firmas\u0131 aras\u0131na girdi.<\/p>\n

Ekonomi ve i\u015f d\u00fcnyas\u0131 portal\u0131 Turkishtime\u2019\u0131n gelenekselle\u015fen T\u00fcrkiye Ar-Ge 250 Ara\u015ft\u0131rmas\u0131\u2019n\u0131n 2024 verileriyle haz\u0131rlanan sonu\u00e7lar\u0131 a\u00e7\u0131kland\u0131. T\u00fcrkiye ihracat s\u0131ralamas\u0131ndaki ilk 500 firmaya, Bilim, Sanayi ve Teknoloji Bakanl\u0131\u011f\u0131\u2019na kay\u0131tl\u0131 Ar-Ge merkezi bulunan firmalara ve Ar-Ge datalar\u0131n\u0131 Kamu Ayd\u0131nlatma Platformu\u2019yla payla\u015fan firmalara y\u00f6nelik anket verileriyle haz\u0131rlanan ara\u015ft\u0131rma sonu\u00e7lar\u0131na g\u00f6re Orzaks\u2019\u0131n \u00fcretim g\u00fcc\u00fc olan Nuvita \u0130la\u00e7, performans\u0131yla ilk 250 firma aras\u0131nda yer ald\u0131.<\/p>\n","protected":false},"author":1,"featured_media":4285,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[48,3],"tags":[],"_links":{"self":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/4281"}],"collection":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4281"}],"version-history":[{"count":6,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/4281\/revisions"}],"predecessor-version":[{"id":4291,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/4281\/revisions\/4291"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/media\/4285"}],"wp:attachment":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4281"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4281"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4281"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}